Open AccessPlatelet-to-lymphocyte ratio but not neutrophil-to-lymphocyte ratio predicts high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndrome
Author(s) -
Efe Edem,
İbrahim Kocayiğit,
Pabuccu Mustafa Türker,
Murat Küçükukur,
Erkan Alpaslan,
Sedat Taş,
Çil Alper,
Aksoy Murat Necati,
Vural Mustafa Gökhan,
Bahri Akdeniz
Publication year - 2016
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.186205
Subject(s) - clopidogrel , medicine , acute coronary syndrome , platelet , odds ratio , aspirin , receiver operating characteristic , ticagrelor , confidence interval , cardiology , lymphocyte , neutrophil to lymphocyte ratio , platelet activation , area under the curve , gastroenterology , myocardial infarction
Dual antiplatelet therapy (DAPT), consisting of clopidogrel and aspirin, is the main-stay treatment of acute coronary syndromes (ACS). However, major adverse cardiovascular events may occur even in patients undergoing DAPT, and this has been related to the variable pharmacodynamic efficacy of these drugs, especially clopidogrel. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are novel inflammatory markers for cardiovascular risk stratification, which may reflect an inflammatory state and thus high on-treatment platelet reactivity (HPR).